Erol Fikrig - Infectious Diseases

Author Information

Erol Fikrig is affiliated with the Department of Internal Medicine at Yale University School of Medicine, located in New Haven, Connecticut, USA. His research primarily focuses on infectious diseases, with a strong emphasis on the study of Lyme disease and vector-borne infections. Erol Fikrig has made significant contributions to understanding the interactions between pathogens and their vectors, which has implications for developing new therapeutic and preventive strategies.

Research Contributions

Erol Fikrig has contributed extensively to the field of infectious diseases, particularly in the context of Lyme disease. His research includes exploring the molecular mechanisms by which the Lyme disease agent interacts with its arthropod vector, investigating host-pathogen interactions, and developing novel vaccine strategies to prevent Lyme disease transmission. His recent work includes studies on mRNA vaccination for tick resistance and the identification of potential vaccine candidates through the analysis of tick-exposed human sera. Additionally, he has explored the role of mosquito salivary proteins in early host infection by Plasmodium, showcasing his diverse research interests within vector-borne diseases.

Aliases

Erol Fikrig is also known by aliases such as E Fikrig and E. Fikrig. However, the use of his full name provides the most comprehensive identification in academic and professional contexts.

Publication and Citation Metrics

Metric	Value
Total Number of Papers	462
Total Citation Count	32,100
h-index	99

Publications:

Correction: The Lyme disease agent co-opts adiponectin receptor-mediated signaling in its arthropod vector

DOI: 10.7554/elife.77794

Year: 2022

Use of host lipids by the Lyme disease spirochete may lead to biomarkers

DOI: 10.1172/JCI158254

Year: 2022

CD36 homologs determine microbial resistance to the Lyme disease spirochete

DOI: 10.1101/2022.02.09.479763

Year: 2022

Probing an Ixodes ricinus salivary gland yeast surface display with tick-exposed human sera to identify novel candidates for an anti-tick vaccine.

DOI: 10.1038/s41598-021-92538-9

Year: 2021

Author response: The Lyme disease agent co-opts adiponectin receptor-mediated signaling in its arthropod vector

DOI: 10.7554/elife.72568.sa2

Year: 2021

Immunomodulation by Mosquito Salivary Protein AgSAP Contributes to Early Host Infection by Plasmodium

DOI: 10.1128/mBio.03091-21

Year: 2021

An Essential Role of UBXN3B in B Lymphopoiesis

DOI: 10.1101/2021.03.04.433919

Year: 2021

mRNA vaccination induces tick resistance and prevents transmission of the Lyme disease agent

DOI: 10.1126/scitranslmed.abj9827

Year: 2021

A Mosquito AgTRIO Monoclonal Antibody Reduces Early Plasmodium Infection of Mice

DOI: 10.1128/IAI.00359-21

Year: 2021

Tick immunity using mRNA, DNA and protein-based Salp14 delivery strategies.

DOI: 10.1016/j.vaccine.2021.11.003

Year: 2021

What Are Functional Assays?

How Does the NIH Collaborate with Other Organizations?

What is Antimicrobial Resistance?

What Role Does Sanitization Play in Infection Control?

What are the Limitations of Serological Tests?

What is Plasmodium?

How is Zika Virus Transmitted?

What are Future Directions for Schistosomiasis Research?

When is Dexamethasone prescribed in infectious diseases?

What Types of Pathogens are Commonly Spread by Direct Contact?

Partnered Content Networks

Relevant Topics